Abstract
Akt (protein kinase B) is a serine/threonine kinase which is a central regulator of widely divergent cellular processes including proliferation, differentiation, migration, survival and metabolism. Akt is activated by a variety of stimuli, through growth factor receptors, in phosphatidylinositol 3-kinase (PI3K)-dependent manner. Akt is also negatively regulated by the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN). A disruption of normal Akt/PKB/PTEN signaling frequently occurs in many human cancers, which plays an important role in cancer development, progression and therapeutic resistance. Numerous studies have revealed the blockage of Akt signaling to result in apoptosis and growth inhibition of tumor cells. Therefore, this signaling pathway, including both upstream and downstream of Akt, has recently attracted considerable attention as a new target for effective cancer therapeutic strategies. In fact, many inhibitors of Akt pathway have been identified and clinical studies of some agents are ongoing. In this review, we describe Akt signaling pathway components and its cellular functions as well as the alterations in human cancers and the therapeutic approaches for targeting the Akt pathway in cancer.
Keywords: Akt, PI3K, PTEN, mTOR, receptor protein tyrosine kinase, molecular target, cancer
Current Cancer Drug Targets
Title: Deregulation of the Akt Pathway in Human Cancer
Volume: 8 Issue: 1
Author(s): Eriko Tokunaga, Eiji Oki, Akinori Egashira, Noriaki Sadanaga, Masaru Morita, Yoshihiro Kakeji and Yoshihiko Maehara
Affiliation:
Keywords: Akt, PI3K, PTEN, mTOR, receptor protein tyrosine kinase, molecular target, cancer
Abstract: Akt (protein kinase B) is a serine/threonine kinase which is a central regulator of widely divergent cellular processes including proliferation, differentiation, migration, survival and metabolism. Akt is activated by a variety of stimuli, through growth factor receptors, in phosphatidylinositol 3-kinase (PI3K)-dependent manner. Akt is also negatively regulated by the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN). A disruption of normal Akt/PKB/PTEN signaling frequently occurs in many human cancers, which plays an important role in cancer development, progression and therapeutic resistance. Numerous studies have revealed the blockage of Akt signaling to result in apoptosis and growth inhibition of tumor cells. Therefore, this signaling pathway, including both upstream and downstream of Akt, has recently attracted considerable attention as a new target for effective cancer therapeutic strategies. In fact, many inhibitors of Akt pathway have been identified and clinical studies of some agents are ongoing. In this review, we describe Akt signaling pathway components and its cellular functions as well as the alterations in human cancers and the therapeutic approaches for targeting the Akt pathway in cancer.
Export Options
About this article
Cite this article as:
Tokunaga Eriko, Oki Eiji, Egashira Akinori, Sadanaga Noriaki, Morita Masaru, Kakeji Yoshihiro and Maehara Yoshihiko, Deregulation of the Akt Pathway in Human Cancer, Current Cancer Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/156800908783497140
DOI https://dx.doi.org/10.2174/156800908783497140 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date
Recent Patents on Biomarkers Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1
Current Medicinal Chemistry Role of Carbon Monoxide in Kidney Function: Is a little Carbon Monoxide Good for the Kidney?
Current Pharmaceutical Biotechnology Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer
Current Drug Targets Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Polymeric Nanocarriers: New Endeavors for the Optimization of the Technological Aspects of Drugs
Recent Patents on Biomedical Engineering (Discontinued) Identifying Biomarkers of Lung Cancer in the Post-Genomic Era
Current Pharmacogenomics Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice
Current Gene Therapy Retinoic Acid Metabolism and Mechanism of Action: A Review
Current Drug Metabolism Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Current Pharmaceutical Design Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design Recent Advances in Carbon Nanotubes as Delivery Systems for Anticancer Drugs
Current Medicinal Chemistry Antimicrobial Activity of Molluscan Hemocyanins from Helix and Rapana Snails
Current Pharmaceutical Biotechnology